Table 5.

Impact of different demographic and clinial factors on the freqency of side effects in PAH/CTEPH patients: results of the univariate and multivariate regression analyses.

	Univariate Analysis OR (95%CI)	p-Value (LR)	Multivariate Analysis OR (95%CI)	p-Value (Wald)
Age ≥ 60 years	0.2 (0.1–0.5)	0.0000 *	0.3 (0.1–0.5)	0.001 *
Female gender	1.2 (0.7–2.2)	0.7
CTEPH	0.6 (0.4–1.2)	0.2
WHO functional classes 3 and 4	0.5 (0.2–0.9)	0.03 *	0.8 (0.4–1.5)	0.5
Presence of concomitant disease	0.4 (0.2–0.8)	0.02 *	0.7 (0.4–1.5)	0.4

CTEPH—chronic thromboembolic pulmonary hypertension, * p < 0.05.